Shandong Xinhua Pharmaceutical Company Limited (FRA:XIN)

FRA:XIN Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	8,352	8,324	7,956	7,295	6,360	5,949
Other Revenue	142.44	142.44	144.78	207.82	200.54	56.85
Revenue	8,495	8,466	8,101	7,503	6,560	6,006
Revenue Growth (YoY)	1.89%	4.51%	7.97%	14.37%	9.23%	7.13%
Cost of Revenue	6,795	6,481	5,779	5,515	4,824	4,244
Gross Profit	1,699	1,985	2,321	1,988	1,736	1,762
Selling, General & Admin	817.34	1,017	1,287	1,106	929.12	943.96
Research & Development	386.62	413.18	419.24	345.66	341.37	298.35
Other Operating Expenses	47.49	35.88	92.18	65.31	59.27	60.28
Operating Expenses	1,261	1,475	1,809	1,522	1,332	1,303
Operating Income	438.55	510.63	512.15	465.87	403.67	458.77
Interest Expense	-40.38	-39.74	-41.15	-49.71	-53.1	-59.76
Interest & Investment Income	14.77	20.96	21.88	18.83	16.79	11.58
Currency Exchange Gain (Loss)	19.09	19.09	15.42	10.53	-4.18	-24.78
Other Non Operating Income (Expenses)	-4.27	-3.41	-2.72	-3.38	-2.45	-4.46
EBT Excluding Unusual Items	427.76	507.53	505.59	442.15	360.72	381.35
Gain (Loss) on Sale of Assets	1.4	1.42	8.73	5.54	2.07	2.49
Asset Writedown	-7.1	-5.12	-10.29	-2.61	-1.88	-4.43
Other Unusual Items	24.67	29.82	28.65	26.7	60.32	32.23
Pretax Income	446.73	533.65	532.69	471.77	421.23	411.64
Income Tax Expense	48.56	46.94	26.58	45.66	59.16	64.52
Earnings From Continuing Operations	398.17	486.71	506.11	426.11	362.07	347.11
Minority Interest in Earnings	-16.01	-16.69	-9.59	-15.05	-13.53	-22.25
Net Income	382.16	470.02	496.51	411.06	348.55	324.86
Net Income to Common	382.16	470.02	496.51	411.06	348.55	324.86
Net Income Growth	-14.81%	-5.33%	20.79%	17.94%	7.29%	8.30%
Shares Outstanding (Basic)	685	682	674	661	627	622
Shares Outstanding (Diluted)	691	688	692	671	627	627
Shares Change (YoY)	-0.13%	-0.54%	3.20%	6.93%	-0.02%	0.86%
EPS (Basic)	0.56	0.69	0.74	0.62	0.56	0.52
EPS (Diluted)	0.55	0.68	0.72	0.61	0.56	0.52
EPS Growth	-15.48%	-5.56%	18.03%	9.75%	6.89%	8.33%
Free Cash Flow	268.97	155.19	-59.85	513.48	9.89	140
Free Cash Flow Per Share	0.39	0.23	-0.09	0.77	0.02	0.22
Dividend Per Share	0.250	0.275	0.250	0.200	0.150	0.150
Dividend Growth	-9.09%	10.00%	25.00%	33.33%	-	25.00%
Gross Margin	20.01%	23.45%	28.66%	26.50%	26.46%	29.33%
Operating Margin	5.16%	6.03%	6.32%	6.21%	6.15%	7.64%
Profit Margin	4.50%	5.55%	6.13%	5.48%	5.31%	5.41%
Free Cash Flow Margin	3.17%	1.83%	-0.74%	6.84%	0.15%	2.33%
EBITDA	995.96	1,049	1,026	952.48	840.2	842.97
EBITDA Margin	11.72%	12.40%	12.67%	12.70%	12.81%	14.04%
D&A For EBITDA	557.41	538.84	514.09	486.61	436.53	384.2
EBIT	438.55	510.63	512.15	465.87	403.67	458.77
EBIT Margin	5.16%	6.03%	6.32%	6.21%	6.15%	7.64%
Effective Tax Rate	10.87%	8.80%	4.99%	9.68%	14.04%	15.68%
Revenue as Reported	28.45	-	-	7,503	-	6,006
Advertising Expenses	-	7.46	8.95	8.18	11.33	12.84

Source: S&P Global Market Intelligence. Standard template. Financial Sources.